Tyler Beyett, PhD

Research Program

Discovery and Developmental Therapeutics
Email Address

tbeyett@emory.edu

Biography

Tyler S. Beyett, PhD, is an assistant professor in the Department of Pharmacology and Chemical Biology at Emory University School of Medicine.

Dr. Beyett is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute.

Education

Dr. Beyett earned his PhD in Chemical Biology from the Life Sciences Institute at the University of Michigan in the lab of Dr. John Tesmer, where he studied the structure and regulation of GPCR kinases. He was a Ruth L. Kirschstein postdoctoral fellow at the Dana-Farber Cancer Institute and Harvard Medical School with Dr. Michael Eck.

Titles & Roles

Assistant Professor, Department of Pharmacology and Chemical Biology

Emory University School of Medicine

Research

Dr. Beyett's research is primarily focused on the clinical development of allosteric EGFR inhibitors for drug-resistant lung cancers. His lab is generally interested in kinases and phosphatases, which play opposing roles in maintaining balance in most signaling cascades and are often mutated or dysregulated in cancer. His research is focused on 1) new kinase therapeutic strategies and 2) how phosphatases are regulated by protein-protein interactions.

Publications

Title/Journal	Authors	Publication Date
Enantioselective Protein Affinity Selection Mass Spectrometry (EAS-MS). bioRxiv : the preprint server for biology	X Wang, J Sun, S Ahmad, D Yang, F Li, UH Chan, H Zeng, CV Simoben, S Houliston, A Dong, A Bolotokova, E Gibson, M Kutera, P Ghiabi, I Kondratov, T Matviyuk, A Chuprina, D Mavridi, C Lenz, AC Joerger, BD Brown, RB Heath, WW Yue, LK Robbie, TS Beyett, S Müller, S Knapp, R Harding, M Schapira, PJ Brown, V Santhakumar, S Ackloo, CH Arrowsmith, AM Edwards, H Peng, L Halabelian	01/22/2025
Biochemical analysis of EGFR exon20 insertion variants insASV and insSVD and their inhibitor sensitivity. Proceedings of the National Academy of Sciences of the United States of America	H Zhao, TS Beyett, J Jiang, JK Rana, IK Schaeffner, J Santana, PA Jänne, MJ Eck	11/05/2024
Structural Analysis of the Macrocyclic Inhibitor BI-4020 Binding to EGFR Kinase. ChemMedChem	TS Beyett, JK Rana, IK Schaeffner, DE Heppner, MJ Eck	06/17/2024
ZNL0325, a Pyrazolopyrimidine-Based Covalent Probe, Demonstrates an Alternative Binding Mode for Kinases. Journal of medicinal chemistry	Z Li, W Lu, TS Beyett, SB Ficarro, J Jiang, J Tse, AY Kim, JA Marto, J Che, PA Jänne, MJ Eck, T Zhang, NS Gray	02/22/2024
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors. Communications chemistry	F Wittlinger, BC Ogboo, E Shevchenko, T Damghani, CD Pham, IK Schaeffner, BT Oligny, SP Chitnis, TS Beyett, A Rasch, B Buckley, DA Urul, T Shaurova, EW May, EM Schaefer, MJ Eck, PA Hershberger, A Poso, SA Laufer, DE Heppner	02/20/2024
A Constitutive EGFR Kinase Dimer to Study Inhibitor Pharmacology. Molecular pharmacology	JJ Kim, IK Schaeffner, DE Heppner, C To, PA Jänne, TS Beyett, MJ Eck	01/10/2024
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors. Research square	D Heppner, F Wittlinger, B Ogboo, E Shevchenko, T Damghani, C Pham, I Schaeffner, B Oligny, S Chitnis, T Beyett, A Rasch, B Buckley, D Urul, T Shaurova, E May, E Schaefer, M Eck, P Hershberger, A Poso, S Laufer	09/13/2023
Oncogenic K-Ras suppresses global miRNA function. Molecular cell	B Shui, TS Beyett, Z Chen, X Li, G La Rocca, WM Gazlay, MJ Eck, KS Lau, A Ventura, KM Haigis	07/20/2023